OXFY.Y Stock Overview
Engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oxford Nanopore Technologies plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£6.70 |
| 52 Week High | UK£6.77 |
| 52 Week Low | UK£6.70 |
| Beta | 0.79 |
| 11 Month Change | -1.03% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.03% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| OXFY.Y | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.5% |
| 1Y | n/a | 2.8% | 22.7% |
Return vs Industry: Insufficient data to determine how OXFY.Y performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how OXFY.Y performed against the US Market.
Price Volatility
| OXFY.Y volatility | |
|---|---|
| OXFY.Y Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OXFY.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OXFY.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,238 | Gordon Sanghera | nanoporetech.com |
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company operates in Life Science Research Tools and Covid Testing segments. It offers MinION, a portable device for DNA and RNA; GridION, a flexible and self-contained benchtop nanopore sequencer to run and analyse up to five MinION or Flongle flow cells; MinION Mk 1C, a nano pore-based sequencer with analysis software and connectivity for self-contained and portable sequencing; Flongle, an adapter for MinION or GridION that enables DNA sequencing or cDNA sequencing on smaller and single-use flow cells; and PromethION 2 Solo, a sequencer for two PromethION flow cells.
Oxford Nanopore Technologies plc Fundamentals Summary
| OXFY.Y fundamental statistics | |
|---|---|
| Market cap | US$1.58b |
| Earnings (TTM) | -US$202.45m |
| Revenue (TTM) | US$222.32m |
6.7x
P/S Ratio-7.4x
P/E RatioIs OXFY.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXFY.Y income statement (TTM) | |
|---|---|
| Revenue | UK£169.67m |
| Cost of Revenue | UK£79.19m |
| Gross Profit | UK£90.48m |
| Other Expenses | UK£244.99m |
| Earnings | -UK£154.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 53.33% |
| Net Profit Margin | -91.06% |
| Debt/Equity Ratio | 0% |
How did OXFY.Y perform over the long term?
See historical performance and comparison